Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-021104
Filing Date
2025-08-05
Accepted
2025-08-05 20:04:44
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7106
  Complete submission text file 0001415889-25-021104.txt   8773
Mailing Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478
Business Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478 (713) 489-8654
Tvardi Therapeutics, Inc. (Subject) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87880 | Film No.: 251186828
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 535 HAROLD AVENUE NE ATLANTA GA 30307
Business Address
Tweardy Samuel David (Filed by) CIK: 0002066396 (see all company filings)

Type: SCHEDULE 13G/A